A Dose Escalation Study of PF‑06939999 in Participants With Advanced or Metastatic Solid Tumors.

• Advanced Solid Tumors
• Metastatic Solid Tumors

• Drug: PF-06939999
  
  0.5 mg QD orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  0.5 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  1 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  2 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  4 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  8 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  16 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  30 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor
• Drug: PF-06939999
  
  60 mg BID orally on a continuous basis
  Other Name: PRMT5 inhibitor

• Experimental: Dose Level 1
  
  Participants will receive PF-06939999 at 0.5 mg once a day (QD) in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 2
  
  Participants will receive PF-06939999 at 0.5 mg BID in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 3
  
  Participants will receive PF-06939999 at 1 mg twice a day (BID) in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 4
  
  Participants will receive PF-06939999 at 2 mg BID in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 5
  
  Participants will receive PF-06939999 at 4 mg BID in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 6
  
  Participants will receive PF-06939999 at 8 mg BID in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 7
  
  Participants will receive PF-06939999 at 16 mg BID in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 8
  
  Participants will receive PF-06939999 at 30 mg BID in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999
• Experimental: Dose Level 9
  
  Participants will receive PF-06939999 at 60 mg BID in 28 day cycles on a continuous basis
  Intervention: Drug: PF-06939999

Inclusion Criteria:

• Participants who are intolerant or resistant to standard treatment for selected solid tumors
• At least one measurable lesion as defined by RECIST version 1.1
• ECOG Performance Status 0 or 1
• Adequate Bone Marrow Function
• Adequate Renal Function
• Adequate Liver Function
• Resolved acute effects of any prior therapy

Exclusion Criteria:

• Known active uncontrolled or symptomatic CNS metastases.
• Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
• Active, uncontrolled infection
• Known or suspected hypersensitivity to PF-06939999
• Inability to consume or absorb study drug